Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Prioritising CVD prevention therapy - absolute risk versus individual risk factors.

Doust J, Sanders S, Shaw J, Glasziou P.

Aust Fam Physician. 2012 Oct;41(10):805-9.

PMID:
23210106
2.

How do the Australian guidelines for lipid-lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab Study, 1999-2000.

Chen L, Rogers SL, Colagiuri S, Cadilhac DA, Mathew TH, Boyden AN, Peeters A, Magliano DJ, Shaw JE, Zimmet PZ, Tonkin AM; National Vascular Disease Prevention Alliance..

Med J Aust. 2008 Sep 15;189(6):319-22.

PMID:
18803535
3.

Primary prevention of cardiovascular disease: new guidelines, technologies and therapies.

Nelson MR, Doust JA.

Med J Aust. 2013 Jun 17;198(11):606-10.

PMID:
23919708
4.

Influence of cardiovascular absolute risk assessment on prescribing of antihypertensive and lipid-lowering medications: a cluster randomized controlled trial.

Vagholkar S, Zwar N, Jayasinghe UW, Denney-Wilson E, Patel A, Campbell T, Harris MF.

Am Heart J. 2014 Jan;167(1):28-35. doi: 10.1016/j.ahj.2013.10.002.

5.

Cardiovascular risk factors and recommended lipid goals attainment among patients referred in a tertiary care lipid clinic.

Pirro M, Del Giorno R, Lupattelli G, Mannarino MR, Roscini AR, Covelli D, Schillaci G, Pasqualini L, Bagaglia F, Siepi D, Mannarino E.

Eur J Intern Med. 2011 Aug;22(4):412-7. doi: 10.1016/j.ejim.2011.04.007.

PMID:
21767761
6.

Blood pressure and lipid management fall far short in persons with type 2 diabetes: results from the DIAB-CORE Consortium including six German population-based studies.

Rückert IM, Schunk M, Holle R, Schipf S, Völzke H, Kluttig A, Greiser KH, Berger K, Müller G, Ellert U, Neuhauser H, Rathmann W, Tamayo T, Moebus S, Andrich S, Meisinger C.

Cardiovasc Diabetol. 2012 May 8;11:50.

7.

Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study.

Bongard V, Dallongeville J, Arveiler D, Ruidavets JB, Amouyel P, Wagner A, Ferrières J.

Arch Cardiovasc Dis. 2013 Feb;106(2):93-102. doi: 10.1016/j.acvd.2012.11.003.

8.

Under-utilisation of preventive medication in patients with cardiovascular disease is greatest in younger age groups (PREDICT-CVD 15).

Mehta S, Wells S, Riddell T, Kerr A, Pylypchuk R, Marshall R, Ameratunga S, Chan WC, Thornley S, Crengle S, Harrison J, Drury P, Elley CR, Bell F, Jackson R.

J Prim Health Care. 2011 Jun 1;3(2):93-101.

PMID:
21625656
9.

General practitioners' use of absolute risk versus individual risk factors in cardiovascular disease prevention: an experimental study.

Jansen J, Bonner C, McKinn S, Irwig L, Glasziou P, Doust J, Teixeira-Pinto A, Hayen A, Turner R, McCaffery K.

BMJ Open. 2014 May 15;4(5):e004812. doi: 10.1136/bmjopen-2014-004812.

10.
11.

Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study.

Cobiac LJ, Magnus A, Barendregt JJ, Carter R, Vos T.

BMC Public Health. 2012 Jun 1;12:398. doi: 10.1186/1471-2458-12-398.

13.

Dyslipidaemia in rural Australia: prevalence, awareness, and adherence to treatment guidelines in the Greater Green Triangle Risk Factor Study.

Janus ED, Tideman PA, Dunbar JA, Kilkkinen A, Bunker SJ, Philpot B, Tirimacco R, Mc Namara K, Heistaro S, Laatikainen T.

Med J Aust. 2010 Feb 1;192(3):127-32.

PMID:
20121678
14.

Lipid control in patients with diabetes mellitus.

Betteridge DJ.

Nat Rev Cardiol. 2011 May;8(5):278-90. doi: 10.1038/nrcardio.2011.23. Review.

PMID:
21403658
15.
16.

Lipid treatment guidelines and cardiovascular risk for Aboriginal people in Central Australia.

Luke JN, Brown A, O'Neal DN, O'Dea K, Jenkins AJ, Kelaher M, Best JD, Rowley KG.

Med J Aust. 2009 May 18;190(10):552-6.

PMID:
19450200
17.

Dyslipidemias and the primary prevention of cardiovascular disease: analysis of the FAMUS primary care register.

Xhignesse M, Laplante P, Niyonsenga T, Courteau J, Grant AM.

Can J Cardiol. 2000 Jul;16(7):879-85.

PMID:
10934306
18.

Antihypertensive, antidiabetic and lipid-lowering treatment frequencies in France in 2010.

Tuppin P, Ricci-Renaud P, de Peretti C, Fagot-Campagna A, Gastaldi-Menager C, Danchin N, Alla F, Allemand H.

Arch Cardiovasc Dis. 2013 May;106(5):274-86. doi: 10.1016/j.acvd.2013.02.005.

19.

Framing cardiovascular disease event risk prediction.

Stone JA.

Can J Cardiol. 2011 Mar-Apr;27(2):171-3. doi: 10.1016/j.cjca.2010.12.041. No abstract available.

PMID:
21459265
20.

Landmark lipid-lowering trials in the primary prevention of cardiovascular disease.

Chrispin J, Martin SS, Hasan RK, Joshi PH, Minder CM, McEvoy JW, Kohli P, Johnson AE, Wang L, Blaha MJ, Blumenthal RS.

Clin Cardiol. 2013 Sep;36(9):516-23. doi: 10.1002/clc.22147. Review.

Items per page

Supplemental Content

Support Center